Peginterferon alfa-2b biosimilar - Harvest Moon Pharmaceuticals

Drug Profile

Peginterferon alfa-2b biosimilar - Harvest Moon Pharmaceuticals

Alternative Names: PEG alpha interferon 2b biosimilar - Harvest Moon

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Harvest Moon Pharmaceuticals
  • Class Antineoplastics; Antivirals; Interferons; Polyethylene glycols
  • Mechanism of Action Immunostimulants; Interferon alpha stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Hepatitis C; Multiple myeloma

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Hepatitis-C in USA (SC, Injection)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Multiple-myeloma in USA (SC, Injection)
  • 11 Oct 2013 Peginterferon alfa-2b biosimilar is available for licensing as of 11 Oct 2013. http://harvestmoonpharma.com
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top